We bring you the latest news from the healthcare about the health care in the United Kingdom. Do your have news for us? Contact the editor. Watch also this special movie.

vrijdag 21 april 2017

The Lancet: [News] American Association for Cancer Research Annual Meeting 2017

[News] American Association for Cancer Research Annual Meeting 2017
Results from an open-label, phase 2, basket trial assessing the clinical activity of neratinib in 141 patients with either HER2-mutant or HER3-mutant tumours were presented by David Hyman (Memorial Sloan Kettering Cancer Center, New York, NY, USA). Patients with HER2-mutant lung cancer (n=26), breast cancer (n=25), bladder or urinary tract cancer (n=16), colorectal cancer (n=12), biliary tract cancer (n=9), endometrial cancer (n=7), cervical cancer (n=5), gastro-oesophageal cancer (n=5), and ovarian cancer (n=4), as well as patients with solid tumours not otherwise specified (n=32; of which 15 were HER2-mutant-postive and 17 were HER3-mutant-postive), were enrolled in this study.
Read more

[Articles] Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study
Chemoradiotherapy with radiation doses reduced by 15–20% was associated with high progression-free survival and an improved toxicity profile compared with historical regimens using standard doses. Radiotherapy de-escalation has the potential to improve the therapeutic ratio and long-term function for these patients.
Read more

[Comment] HPV-related oropharyngeal carcinoma de-escalation protocols
Human papillomavirus (HPV) is now recognised as the principal cause of the increasing incidence of oropharyngeal squamous-cell carcinoma in developed countries. HPV-related oropharyngeal squamous-cell carcinomas have epidemiological, molecular, and clinical characteristics different from those caused by classic risk factors (eg, tobacco and alcohol consumption). Most importantly, however, positive HPV status is an independent predictor of improved overall survival and treatment responsiveness.1 Additionally, patients with HPV-related oropharyngeal squamous-cell carcinoma tend to be younger than patients with non-HPV-related disease2 and to have high treatment-related morbidity that can substantially impair quality of life.
Read more

[Articles] Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial
The addition of bevacizumab to standard chemotherapy, followed by maintenance therapy until progression, improved the median overall survival in patients with platinum-sensitive recurrent ovarian cancer. Although the intention-to-treat analysis for overall survival was not significant, our sensitivity analysis based on corrected treatment-free interval stratification indicates that this strategy might be an important addition to the therapeutic armamentarium in these patients.
Read more

[News] Tyrosine kinase-inhibitors and heart failure risk
Tyrosine kinase-inhibiting drugs—used in the treatment of various solid and haematological malignancies—are associated with a significantly increased risk of developing new-onset heart failure, according to new research.
Read more